Figure 2 - MMD Responder Rates Statistically Significant

AEON Biopharma

Responder definition: patient demonstrated a reduction vs. baseline in the number of monthly migraine days (MMD) of ≥50% and ≥75% during weeks 21-24

Format

JPEG

Source

AEON Biopharma

Downloads